GHK-Cu for skin: what the peptide research actually shows

What's this video probably claiming?

Based on the caption and hashtags, this creator is likely telling her audience that GHK-Cu (copper peptide glycyl-L-histidyl-L-lysine) works meaningfully for skin discoloration, crepey texture, and collagen loss, and that topical application is a legitimate delivery route. She's also implying that commercial products underperform because they contain fillers or use subtherapeutic concentrations, nudging viewers toward compounded or more concentrated alternatives. The hashtag use of #melasma alongside #womenover40 suggests she's positioning this as a solution for hyperpigmentation specifically, which is a more specific and less well-supported claim than general skin quality. This framing is common in the peptide-adjacent skincare space right now, and some parts of it are genuinely grounded in real data, while others are extrapolating well beyond what clinical evidence supports.

What does the science actually show?

GHK-Cu does have a reasonably interesting body of research behind it, particularly in wound healing and fibroblast stimulation. Pickart et al. (2015, Journal of Aging Science) documented GHK-Cu's role in upregulating collagen, elastin, and glycosaminoglycan synthesis in vitro. A double-blind study by Leyden et al. (2009, Journal of the American Academy of Dermatology) found a peptide-containing cream (including GHK-Cu) produced measurable improvements in fine lines and skin density over 12 weeks. Concentrations used in studied formulations typically range from 0.5% to 2%. The collagen angle has more support than the pigmentation angle. On melanin and discoloration, the data is thin. Some in vitro work suggests copper peptides can modulate melanocyte activity, but there are no strong randomized controlled trials showing GHK-Cu reliably treats melasma or post-inflammatory hyperpigmentation in humans at any concentration.

Where does the social media noise diverge from clinical reality?

The creator's suggestion that commercial products fail because of fillers or low concentration sounds plausible but is largely unverifiable without formulation data. Peptide stability in topical vehicles is a real technical challenge. GHK-Cu degrades when exposed to oxidizing agents, certain preservatives, and pH extremes, so formulation quality does matter. But the leap from "commercial products are underperforming" to "you need a compounded or purer version" is doing a lot of work without evidence. More importantly, the implicit framing that GHK-Cu treats melasma is a stretch. Melasma is notoriously treatment-resistant, and the standard of care involves tretinoin, hydroquinone, azelaic acid, and sun protection. No peptide is close to matching that evidence base for pigmentation. Using GHK-Cu hashtag #melasma without that context is misleading to a viewer who might delay or skip effective treatment.

What should you actually know?

GHK-Cu is not a fringe ingredient. It has legitimate research in the wound healing and skin aging space, and topical use is real, with studies using it at concentrations between 0.5% and 2% over 8 to 12 week periods. But legitimate does not mean proven for everything being claimed here. Collagen support and texture improvement have the strongest data. Skin discoloration and melasma claims are weakly supported at best. If you are dealing with melasma specifically, a dermatologist conversation is more useful than a TikTok peptide rabbit hole. The "commercial products don't work" framing should be scrutinized. Some do contain meaningful concentrations; some do not. Without third-party testing data on specific products, that claim is conjecture. Anyone considering a compounded GHK-Cu topical should work with a licensed provider, not a social media recommendation, to evaluate formulation quality and appropriateness for their skin condition.